Detalles de la búsqueda
1.
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With ß-Thalassemia.
J Clin Pharmacol
; 61(1): 52-63, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32696522
2.
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
CPT Pharmacometrics Syst Pharmacol
; 9(7): 395-404, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32602651
3.
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Clin Cancer Res
; 10(13): 4374-82, 2004 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15240525
4.
Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Int J Oncol
; 41(2): 639-51, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22580986
5.
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.
Mol Cancer Ther
; 8(9): 2517-25, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19755512
6.
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Cancer Res
; 68(4): 1162-9, 2008 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18281492
Resultados
1 -
6
de 6
1
Próxima >
>>